These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 21497176)

  • 21. IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model.
    Gomez-Cabrero A; Wrasidlo W; Reisfeld RA
    PLoS One; 2013; 8(8):e73607. PubMed ID: 24014113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hybrid Mesoporous-Microporous Nanocarriers for Overcoming Multidrug Resistance by Sequential Drug Delivery.
    Wang L; Guan H; Wang Z; Xing Y; Zhang J; Cai K
    Mol Pharm; 2018 Jul; 15(7):2503-2512. PubMed ID: 29768014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanotechnology applied to overcome tumor drug resistance.
    Gao Z; Zhang L; Sun Y
    J Control Release; 2012 Aug; 162(1):45-55. PubMed ID: 22698943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colon cancer: cancer stem cells markers, drug resistance and treatment.
    Kozovska Z; Gabrisova V; Kucerova L
    Biomed Pharmacother; 2014 Oct; 68(8):911-6. PubMed ID: 25458789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
    Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
    Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
    Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-functional nanocarriers to overcome tumor drug resistance.
    Jabr-Milane LS; van Vlerken LE; Yadav S; Amiji MM
    Cancer Treat Rev; 2008 Nov; 34(7):592-602. PubMed ID: 18538481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.
    Dinic J; Podolski-Renic A; Stankovic T; Bankovic J; Pesic M
    Curr Pharm Des; 2015; 21(38):5589-604. PubMed ID: 26429711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotechnology approaches for personalized treatment of multidrug resistant cancers.
    Minko T; Rodriguez-Rodriguez L; Pozharov V
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1880-95. PubMed ID: 24120655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using nanotechnology to progress the utilization of marine natural products in combating multidrug resistance in cancer: A prospective strategy.
    Bhusare N; Gade A; Kumar MS
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23732. PubMed ID: 38769657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for cancer therapy].
    Chen WG; Wang SB
    Yao Xue Xue Bao; 2013 Jul; 48(7):1091-8. PubMed ID: 24133974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
    Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
    J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The multi-factorial nature of clinical multidrug resistance in cancer.
    Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
    Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
    Mohammad IS; Teng C; Chaurasiya B; Yin L; Wu C; He W
    Int J Pharm; 2019 Feb; 557():304-313. PubMed ID: 30599232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.
    Al-Akra L; Bae DH; Sahni S; Huang MLH; Park KC; Lane DJR; Jansson PJ; Richardson DR
    J Biol Chem; 2018 Mar; 293(10):3562-3587. PubMed ID: 29305422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progression on Multifunctional Nanoparticles Interfering with Cell Membrane Transporters-associated Drug Resistance].
    Jiang WX; Ren JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Aug; 43(4):620-627. PubMed ID: 34494535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applications of Nanotechnology-based Approaches to Overcome Multi-drug Resistance in Cancer.
    Kalave S; Hegde N; Juvale K
    Curr Pharm Des; 2022; 28(38):3140-3157. PubMed ID: 35366765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
    Milane L; Duan Z; Amiji M
    Mol Pharm; 2011 Feb; 8(1):185-203. PubMed ID: 20942457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
    Erin N; Grahovac J; Brozovic A; Efferth T
    Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.